Oxford Biomedica (OXB) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Jul 2017 08:47 AM
RNS
Director Dealings / Market Share Sale and Purchase
17 Jul 2017 12:31 PM
RNS
Director Dealings
14 Jul 2017 04:49 PM
RNS
Director/PDMR Shareholding
14 Jul 2017 03:30 PM
RNS
PDMR Shareholding
14 Jul 2017 11:41 AM
RNS
LTIP for Long Term Incentive Plan
13 Jul 2017 12:38 PM
RNS
Director Dealings / Market Share Sale and Purchase
13 Jul 2017 07:15 AM
RNS
Holdings in Company
13 Jul 2017 07:00 AM
RNS
FDA AdCom Recommends CTL019 for Approval
11 Jul 2017 09:29 AM
RNS
Director Dealings / Market Share Sale and Purchase
07 Jul 2017 10:15 AM
RNS
Hardman Research: Major deal to supply Novartis
06 Jul 2017 07:15 AM
RNS
Holding(s) in Company
06 Jul 2017 07:00 AM
RNS
Major Commercial and Clinical Supply Agreement
03 Jul 2017 02:20 PM
RNS
Total Voting Rights
03 Jul 2017 02:18 PM
RNS
Block Listing
30 Jun 2017 10:38 AM
RNS
Refinancing of Debt Facility
23 Jun 2017 10:12 AM
RNS
Director Dealings / Market Share Purchase
14 Jun 2017 03:00 PM
RNS
Findings from Phase II JULIET Study
07 Jun 2017 07:00 AM
RNS
OXB notes FDA Advisory Committee to review CTL019
02 Jun 2017 07:00 AM
RNS
OXB to Present at Jefferies Healthcare Conference
01 Jun 2017 12:22 PM
RNS
Total Voting Rights
24 May 2017 01:55 PM
RNS
Director/PDMR Shareholding
23 May 2017 02:03 PM
RNS
Result of AGM
04 May 2017 08:46 AM
RNS
Total Voting Rights
28 Apr 2017 07:00 AM
RNS
Annual Report and Accounts & AGM Notification
24 Apr 2017 10:17 AM
RNS
Director/PDMR Shareholding
04 Apr 2017 07:00 AM
RNS
Holding(s) in Company
03 Apr 2017 09:11 AM
RNS
Total Voting Rights
31 Mar 2017 07:15 AM
RNS
Hardman: Delivering commercial gene-therapy vector
30 Mar 2017 07:02 AM
RNS
BLA filing for CTL019
27 Mar 2017 10:44 AM
RNS
Publication in the Journal Nature Communications
23 Mar 2017 01:47 PM
RNS
Director Dealings
22 Mar 2017 07:00 AM
RNS
Holding(s) in Company
16 Mar 2017 07:00 AM
RNS
PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2016
10 Mar 2017 07:00 AM
RNS
Notice of Preliminary Results
01 Mar 2017 10:24 AM
RNS
Total Voting Rights
28 Feb 2017 07:00 AM
RNS
Appointment of New Chief Financial Officer
24 Feb 2017 09:36 AM
RNS
Director Dealings
24 Feb 2017 07:00 AM
RNS
Results of TroVax® in Advanced Colorectal Cancer
01 Feb 2017 10:09 AM
RNS
Total Voting Rights
25 Jan 2017 09:02 AM
RNS
Director/PDMR Shareholding
24 Jan 2017 04:34 PM
RNS
Director Dealings / Market Share Purchase
24 Jan 2017 09:31 AM
RNS
Director/PDMR Shareholding
23 Jan 2017 09:57 AM
RNS
Director/PDMR Shareholding
03 Jan 2017 09:30 AM
RNS
Block Listing Return
03 Jan 2017 09:28 AM
RNS
Total Voting Rights
20 Dec 2016 08:57 AM
RNS
Director/PDMR Shareholding
12 Dec 2016 10:52 AM
RNS
Block listing application
06 Dec 2016 09:15 AM
RNS
Director/PDMR Shareholding
05 Dec 2016 10:25 AM
RNS
Findings Reported by Novartis on CTL-019 at ASH
05 Dec 2016 09:43 AM
RNS
Director/PDMR Shareholding

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.

Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.

Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.

UK 100